StreetAlpha.app
Home › Stocks › TNGX

Tango Therapeutics, Inc. (TNGX)

Healthcare
$22.11
▼ −8.52%
LAST CLOSE · NOV 17

Tango Therapeutics develops targeted cancer medicines that aim to kill tumor cells with specific genetic alterations. It last closed at $22.11 on Nov 17, down 8.52% on the day. The average 12-month price target from 3 analysts is $51.33 (+132.2% from the last close), with a high of $67.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in TNGX, 100% of them bullish and 0% bearish. In the past 30 days there were 7 dark pool prints totaling $12.4M, the largest $6.3M.

AI Auto Pilots
Is TNGX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$208.0M
EPS (diluted)
−$1.38
Free cash flow
−$150.4M
Valuation
Market cap
$3.7B
169.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$86.8M
At Sep 30
Shareholder equity
$980.2M
Shares outstanding
169.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $37.0M$37.0MFY2021FY2022: $24.9M$24.9MFY2022FY2023: $36.5M$36.5MFY2023FY2024: $42.1M$42.1MFY2024FY2025: $62.4M$62.4MFY2025

From TNGX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on TNGX in the past 90 days
Average 12-month target
$51.33
▲ 132.2% upside

Based on 3 analysts who set a price target on TNGX in the past 90 days. The average target is $51.33, with a high of $67.00 and a low of $40.00, compared with the last close of $22.11.

Low $40.00Avg $51.33High $67.00
Blue marker: last close $22.11
Highest target$67.00
Average target$51.33
Lowest target$40.00
Latest rating changes
JP MorganTarget raised
Nov 10Buy$46 → $47
WedbushMaintained
Nov 10Buy$40
HC Wainwright & Co.Target lowered
Nov 10Buy$68 → $67
HC Wainwright & Co.Target raised
Aug 18Buy$66 → $68
GuggenheimMaintained
Aug 12Buy$35
DateFirmActionRatingPrice target
Nov 10JP MorganTarget raisedBuy$46 → $47
Nov 10WedbushMaintainedBuy$40
Nov 10HC Wainwright & Co.Target loweredBuy$68 → $67
Aug 18HC Wainwright & Co.Target raisedBuy$66 → $68
Aug 12GuggenheimMaintainedBuy$35
Loading…

Technical Analysis

TNGX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 6% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the swing low (Oct 30) at $21.71, and the nearest resistance the swing high (May 21) at $22.24.

Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.9%/day
Key levels
$34.3952 week high+55.5%
$25.23100 day average+14.1%
$23.60Pivot R1+6.7%
$23.5550 day average+6.5%
$23.5320 day average+6.4%
$23.01200 day average+4.1%
$22.83Pivot+3.3%
$22.24Swing high (May 21)+0.6%
$22.11Last close
$21.71Swing low (Oct 30)−1.8%
$21.33Pivot S1−3.5%
$7.6952 week low−65.2%
Indicators
RSI (14)45.19Middle of its rangeNeutral
MACD0.09Above its signal lineBullish
Stochastic55.8Middle of its rangeNeutral
ADX (14)13.5No clear trend
Williams %R-76.5Oversold below −80, overbought above −20Neutral
CCI (20)-41.0Oversold below −100, overbought above 100Neutral
Rate of change−4.6%Change over 10 sessionsBearish
ATR (14)$1.96Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TNGX

What happened before

See how TNGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TNGX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TNGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
2
100%
Bearish
0
0%
Date span
Sep 16 – Sep 16
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
7
Notional
$12.4M
Largest print
$6.3M
Loading…

TNGX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲156 buying vs 101 selling
  • ▼Held by funds -0.7 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding257247+4.0%
In funds' top 1019190.0%
Held by funds126.0%126.7%−0.7 pts
New / increased46 / 11073 / 102−10.9%
Reduced / sold out66 / 3555 / 23+29.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TNGX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TNGX is in one of them and how their past TNGX trades turned out.

TNGX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TNGX in an article yet. Here's the latest on the wider market.

About Tango Therapeutics

Tango Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops targeted cancer medicines. Its lead candidates are small molecule drugs designed to kill cancer cells that carry specific genetic changes while largely sparing normal cells. Its main programs target the PRMT5 protein in cancers with a specific gene deletion, including pancreatic and lung cancers and glioblastoma, a type of brain cancer. The company aims to treat patients whose tumors share these genetic features.

Headquarters
Boston, MA
Founded
2017